Clinical Trial Update: A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer [Phase 2]

View source ↗

Summary

ClinicalTrials.gov entry notes that a Phase 2 trial of regorafenib plus lorigerlimab for locally recurrent or regrowing pMMR/MSS localized rectal cancer has bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Lorigerlimab (lorigerlimab)
• Stivarga (regorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Rectal Cancer, Rectal Cancer Recurrent | Phase 2 | Status: WITHDRAWN